SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (281)8/26/2002 5:15:13 PM
From: JFitnich  Read Replies (1) of 508
 
Wilder,

AH&H had this in the report:

"Top-line data from the Phase III Actimmune study are expected the last three days of August or the first week of September."

FWIW.

I own ITMN and will most likely buy some more if PH3 data is good. I can live with paying up for good results (if endpoints are hit). If the trial doesn't reach stat sig, then I'll have to dig in and figure out my next move.

Honestly, after reading the report, it sounded to me like the results would show trend toward improvement, but might not hit the endpoints.

I agree though, some good news would be nice.

JF
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News